Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MethylGene has filed an investigational new drug application with the FDA for MGCD265, its multi-targeted kinase inhibitor.
Subscribe to our email newsletter
MGCD265 targets the c-MET, VEGFR1, VEGFR2, VEGFR3, Tie-2 and Ron receptor tyrosine kinases, which appear to play key roles in tumor development and survival, blood vessel formation (angiogenesis) and cancer cell metastasis.
Donald Corcoran, president and CEO of MethylGene, said: “MGCD265 has the potential to be clinically tested in a number of solid tumor types. This compound, along with MGCD0103, our HDAC inhibitor, provides MethylGene with a pipeline of compounds in areas of significant scientific and industry interest.”